ライフサイエンスコーパス: argininosuccinate

1 transported to cytosol and incorporated into argininosuccinate.

2 ed with l-citrulline increased the levels of argininosuccinate, an enzyme that metabolizes l-citrulli

3 tained unchanged during the evolution of the argininosuccinate gene are able to change in the pseudog

4 With constitutively expressed argininosuccinate lyase (AL), AS confers cells with an A

5 zymes, argininosuccinate synthetase (AS) and argininosuccinate lyase (AL).

6 Argininosuccinate lyase (ASL) is required for the synthe

7 urea cycle disorder caused by deficiency of argininosuccinate lyase (ASL) with a wide clinical spect

8 zed by argininosuccinate synthase (Ass1) and argininosuccinate lyase (Asl), which would lead to abund

9 We show that a hypomorphic mouse model of argininosuccinate lyase (encoded by Asl) deficiency has

10 inate synthetase deficiency (0.22 +/- 0.03), argininosuccinate lyase deficiency (0.35 +/- 0.11), and

11 inosuccinate synthetase mRNA but did express argininosuccinate lyase mRNA, suggesting that the argini

12 tures in the fumarase superfamily, including argininosuccinate lyase, delta-crystallin, fumarase, and

13 Together, these three enzymes, eNOS, AS, and argininosuccinate lyase, make up the citrulline-NO cycle

14 re identified as argininosuccinate synthase, argininosuccinate lyase, neuronal nitric-oxide synthase,

15 accharomyces cerevisiae counterparts, namely argininosuccinate lyase, PR-aminoimidazolesuccinocarboxa

16 enzymes, argininosuccinate synthase (AS) and argininosuccinate lyase, providing the substrate arginin

17 suppressed pyrimidine biosynthetic pathway, argininosuccinate lyase-encoding, and ABC transporter-re

18 wo steps by argininosuccinate synthetase and argininosuccinate lyase.

19 ne is recycled to l-arginine by two enzymes, argininosuccinate synthase (AS) and argininosuccinate ly

20 Argininosuccinate synthase (AS) catalyzes the rate-limit

21 Argininosuccinate synthase (AS) is a ubiquitous enzyme i

22 Based on the integral role that argininosuccinate synthase (AS) plays in the production

23 used to selectively reduce the expression of argininosuccinate synthase (AS), because the only known

24 Argininosuccinate synthase (ASS) is the rate-limiting en

25 ught to fuel arginine synthesis catalyzed by argininosuccinate synthase (Ass1) and argininosuccinate

26 is pathway associated with overexpression of argininosuccinate synthase (ASS1) and arginosuccinate ly

27 Argininosuccinate synthase (ASS1) is a urea cycle enzyme

28 , CLOCK directly acetylates K165 and K176 of argininosuccinate synthase (ASS1) to inactivate ASS1, wh

29 es in the arginine-recycling pathway enzymes argininosuccinate synthase and ornithine transcarbamylas

30 0461) of H. influenzae, the gene encoding an argininosuccinate synthase homolog, and a change in the

31 ucocorticoid-induced leucine zipper protein, argininosuccinate synthase, and human prostaglandin tran

32 ven up-regulated proteins were identified as argininosuccinate synthase, argininosuccinate lyase, neu

33 also inhibited cytokine induction in CMEC of argininosuccinate synthase, the rate-limiting enzyme for

34 Given the different roles ascribed for argininosuccinate synthase, urea versus NO production, t

35 quires the sequential action of two enzymes, argininosuccinate synthetase (AS) and argininosuccinate

36 anomas and other cancers that do not express argininosuccinate synthetase (AS), the rate-limiting enz

37 inducible isoform of NO synthase (iNOS) and argininosuccinate synthetase (AS).

38 acy of ADI-PEG20 is directly correlated with argininosuccinate synthetase (ASS) deficiency.

39 ted urea cycle disorder that is caused by an argininosuccinate synthetase (ASS) enzyme deficiency.

40 gh energy demand, the ornithine cycle enzyme argininosuccinate synthetase (ASS) is a principle site o

41 nous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers.

42 two-hybrid screening of PRMT7 and identified argininosuccinate synthetase (ASS1) as a potential inter

43 The latter lack argininosuccinate synthetase (ASS1) making them auxotrop

44 ed to influence HSV-1 replication, including argininosuccinate synthetase 1 (AS1), which consumes asp

45 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors b

46 s study, we focused on the urea cycle enzyme argininosuccinate synthetase 1 (ASS1) as a therapeutic t

47 ynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced.

48 Argininosuccinate synthetase 1 (ASS1) is the key enzyme

49 Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for

50 inine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers,

51 synthesized from citrulline in two steps by argininosuccinate synthetase and argininosuccinate lyase

52 le metabolism characterized by deficiency of argininosuccinate synthetase and consequent life-threate

53 Because of decreased expression of argininosuccinate synthetase and/or ornithine transcarba

54 fected with an expression plasmid containing argininosuccinate synthetase cDNA.

55 uished asymptomatic heterozygous carriers of argininosuccinate synthetase deficiency (0.22 +/- 0.03),

56 cinoma (HCC) is an arginine auxotroph due to argininosuccinate synthetase I deficiency.

57 of melanoma and HCC is due to the absence of argininosuccinate synthetase in these cells and that an

58 cient Spf(ash) mouse and the neonatal lethal argininosuccinate synthetase knockout mouse.

59 Melanomas and HCCs did not express argininosuccinate synthetase mRNA but did express argini

60 1-deleted adenoviral vector expressing human argininosuccinate synthetase resulted in transduction of

61 Argininosuccinate synthetase, a key enzyme in the metabo

62 loid leukemias (AMLs) have low expression of argininosuccinate synthetase-1 (ASS1), rendering AML cel

63 ical enzyme required for arginine synthesis, argininosuccinate synthetase-1 (ASS1).

64 ells was a result of an inability to produce argininosuccinate synthetase.

65 We sequenced three argininosuccinate-synthetase-processed pseudogenes (PsiA